F

Faes Farma SA
MAD:FAE

Watchlist Manager
Faes Farma SA
MAD:FAE
Watchlist
Price: 5.22 EUR 1.56% Market Closed
Market Cap: €1.7B

Net Margin

18.5%
Current
Declining
by 1.9%
vs 3-y average of 20.4%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
18.5%
=
Net Income
€105.1m
/
Revenue
€568.1m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
18.5%
=
Net Income
€105.1m
/
Revenue
€568.1m

Peer Comparison

Country Company Market Cap Net
Margin
ES
Faes Farma SA
MAD:FAE
1.6B EUR
Loading...
US
Eli Lilly and Co
NYSE:LLY
969.6B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
547.3B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.1B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.4B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
271.3B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
148.3B USD
Loading...
FR
Sanofi SA
PAR:SAN
93.8B EUR
Loading...

Market Distribution

In line with most companies in Spain
Percentile
69th
Based on 821 companies
69th percentile
18.5%
Low
-9 204.1% — 1.8%
Typical Range
1.8% — 19%
High
19% — 603.4%
Distribution Statistics
Spain
Min -9 204.1%
30th Percentile 1.8%
Median 7.6%
70th Percentile 19%
Max 603.4%

Faes Farma SA
Glance View

Faes Farma SA, a notable player in the pharmaceutical arena, has orchestrated its operations with the precision of a seasoned conductor. Rooted in Spain with an impressive international reach, the company blends research prowess with adept production capabilities. Central to its modus operandi is the development, manufacture, and commercialization of a wide range of pharmaceutical products and nutritional supplements. With science as its guiding star, Faes Farma dedicates substantial resources to research and development, ensuring a pipeline filled with innovative treatments that cater to diverse medical needs. The company has carved its niche by focusing on therapeutic areas such as allergy, dermatology, and the central nervous system, allowing it to create specialized solutions that resonate well with healthcare providers and patients alike. The company’s revenue engine is driven primarily by its robust product sales, enhanced by strategic partnerships and licensing agreements that bolster its market presence both in Spain and across global markets. Through rigorous production processes, Faes Farma ensures the delivery of high-quality medications, matching industry standards and fostering consumer trust. Additionally, its geographical diversification, with subsidiaries and distribution channels spreading across Europe, Latin America, and Africa, underpins its economic durability. By marrying innovation with strategic commercial tactics, Faes Farma has deftly navigated the complexities of the pharmaceutical landscape, ensuring not only profitability but also the sustained delivery of health-enhancing products to the global community.

FAE Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
18.5%
=
Net Income
€105.1m
/
Revenue
€568.1m
What is Faes Farma SA's current Net Margin?

The current Net Margin for Faes Farma SA is 18.5%, which is below its 3-year median of 20.4%.

How has Net Margin changed over time?

Over the last 3 years, Faes Farma SA’s Net Margin has decreased from 19.6% to 18.5%. During this period, it reached a low of 18.5% on Sep 30, 2025 and a high of 22.6% on Dec 31, 2024.

Back to Top